23andMe DNA Ancestry test kit - add to cart

Ancestry
Service
$99  $79 *
add to cart


23andMe DNA Health and Ancestry test kit - add to cart

recommended

Health +
Ancestry Service 
$199  $99 *
add to cart

Important test info

How it works

saliva collection tube

  • Saliva collection kit
  • Specimen bag
  • Step by step instructions
  • Funnel lid
  • Saliva collection tube
  • Tube container
  • Tube cap

Order

Order a 23andMe Health + Ancestry Service
or 23andMe Ancestry Service

Spit

Register your saliva collection tube

Spit in the tube provided
following the full instructions in the kit insert

Mail it back in the pre-paid package

Discover

Track the lab processing status online

Discover what your DNA
says about you!

Behind the Scene: Lab Processing Overview

The latest science. Results you can trust.

– Our Genetic Health Risk** and Carrier Status** reports meet FDA criteria for being scientifically and clinically valid

– All saliva samples are processed in CLIA-certified and CAP-accredited labs

– Our DNA collection kit is FDA-cleared for use with our Genetic Health Risk and Carrier Status reports

– Our kit is manufactured in accordance with FDA’s Good Manufacturing Practice regulations

– Genotyping is a well-established and reliable platform for analyzing DNA

– Our team of scientists and medical experts uses a robust process to develop reports to ensure validity

– Ancestry percentages are derived from our powerful, well-tested system that provides you with ancestry estimates down to the 0.1%

Privacy is in our DNA

Everyone deserves a secure, private place to explore and understand their genetics. At 23andMe, we put you in control of deciding what information you want to learn and what information you want to share.

For specific details about our practices, see our privacy statement, terms of service,research consent document, sample storage consent document and frequently asked questions.

We’re committed to complying with the EU’s new data protection law, referred to as the GDPR. Visit our GDPR page to learn about our data protection approach.

Please contact us at privacy@23andMe.com if you have questions.

*23andMe kit may NOT be redistributed or resold, must be used for educational purposes by educators and college students located in the United States at an accredited educational institution only, and is subject to 23andMe’s Terms of Service and Privacy Statement. Education discount may NOT be applied to a prior purchase of the 23andMe kit or combined with any other offer or discount. Offer is non-transferable and subject to change without notice. Credit card or Paypal payment. Limit one discounted kit per customer.

**The 23andMe PGS test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/


Ancestry reports

5 reports

  • Ancestry Composition
  • Maternal Haplogroup
  • Paternal Haplogroup
  • Neanderthal Ancestry
  • Your DNA Family


Genetic Health Risk reports*

5+ reports

  • BRCA1/BRCA2 (Selected Variants)

    Genetic risk based on a limited
    set of variants for breast, ovarian
    and other cancers

    3 variants in the BRCA1 and BRCA2 genes; relevant for Ashkenazi Jewish descent

  • Age-Related Macular Degeneration

    Genetic risk for a form of adult-onset vision loss

    2 variants in the ARMS2 and CFH genes; relevant for European descent

  • Alpha-1 Antitrypsin Deficiency

    Genetic risk for lung and liver disease

    2 variants in the SERPINA1 gene; relevant for European descent

  • Celiac Disease

    Genetic risk for gluten-related autoimmune disorder

    2 variants near the HLA-DQB1 and HLA-DQA1 genes; relevant for European descent

  • G6PD Deficiency

    Genetic risk for a form of anemia

    1 variant in the G6PD gene; relevant for African descent

  • Hereditary Hemochromatosis (HFE‑Related)

    Genetic risk for iron overload

    2 variants in the HFE gene; relevant for European descent

  • Hereditary Thrombophilia

    Genetic risk for harmful blood clots

    2 variants in the F2 and F5 genes; relevant for European descent

  • Late-Onset Alzheimer’s Disease

    Genetic risk for a form of dementia

    1 variant in the APOE gene; variant found and studied in many ethnicities

  • Parkinson’s Disease

    Genetic risk for a form of movement impairment

    2 variants in the LRRK2 and GBA genes; relevant for European, Ashkenazi Jewish, North African Berber descent


Wellness reports

5+ reports

  • Alcohol Flush Reaction
  • Caffeine Consumption
  • Deep Sleep
  • Genetic Weight
  • Lactose Intolerance
  • Muscle Composition
  • Saturated Fat and Weight
  • Sleep Movement


Traits reports

15+ traits

  • Asparagus Odor Detection
  • Back Hair (available for men only)
  • Bald Spot (available for men only)
  • Bitter Taste
  • Cheek Dimples
  • Cilantro Taste Aversion
  • Cleft Chin
  • Earlobe Type
  • Early Hair Loss (available for men only)
  • Earwax Type
  • Eye Color
  • Finger Length Ratio
  • Freckles
  • Hair Texture
  • Hair Thickness
  • Light or Dark Hair
  • Misophonia (hatred of the sound of chewing)
  • Newborn Hair
  • Photic Sneeze Reflex
  • Red Hair
  • Skin Pigmentation
  • Sweet vs. Salty
  • Toe Length Ratio
  • Unibrow
  • Wake-Up Time
  • Widow’s Peak


Carrier Status reports*

40+ reports

  • ARSACS

    1 variant in the SACS gene; relevant for French Canadian descent

  • Agenesis of the Corpus Callosum with Peripheral Neuropathy

    1 variant in the SLC12A6 gene; relevant for French Canadian descent

  • Autosomal Recessive Polycystic Kidney Disease

    3 variants in the PKHD1 gene

  • Beta Thalassemia and Related Hemoglobinopathies

    10 variants in the HBB gene; relevant for Sardinian, Cypriot, Italian/Sicilian, Greek descent

  • Bloom Syndrome

    1 variant in the BLM gene; relevant for Ashkenazi Jewish descent

  • Canavan Disease

    3 variants in the ASPA gene; relevant for Ashkenazi Jewish descent

  • Congenital Disorder of Glycosylation Type 1a (PMM2-CDG)

    2 variants in the PMM2 gene; relevant for Danish descent

  • Cystic Fibrosis

    29 variants in the CFTR gene; relevant for Ashkenazi Jewish, European, Hispanic/Latino descent

  • D-Bifunctional Protein Deficiency

    2 variants in the HSD17B4 gene

  • Dihydrolipoamide Dehydrogenase Deficiency

    1 variant in the DLD gene; relevant for Ashkenazi Jewish descent

  • Familial Dysautonomia

    1 variant in the IKBKAP gene; relevant for Ashkenazi Jewish descent

  • Familial Hyperinsulinism (ABCC8-Related)

    3 variants in the ABCC8 gene; relevant for Ashkenazi Jewish descent

  • Fanconi Anemia Group C

    3 variants in the FANCC gene; relevant for Ashkenazi Jewish descent

  • GRACILE Syndrome

    1 variant in the BCS1L gene; relevant for Finnish descent

  • Gaucher Disease Type 1

    3 variants in the GBA gene; relevant for Ashkenazi Jewish descent

  • Glycogen Storage Disease Type Ia

    1 variant in the G6PC gene; relevant for Ashkenazi Jewish descent

  • Glycogen Storage Disease Type Ib

    2 variants in the SLC37A4 gene

  • Hereditary Fructose Intolerance

    4 variants in the ALDOB gene; relevant for European descent

  • Herlitz Junctional Epidermolysis Bullosa (LAMB3-Related)

    3 variants in the LAMB3 gene

  • Leigh Syndrome, French Canadian Type

    1 variant in the LRPPRC gene; relevant for French Canadian descent

  • Limb-Girdle Muscular Dystrophy Type 2D

    1 variant in the SGCA gene

  • Limb-Girdle Muscular Dystrophy Type 2E

    1 variant in the SGCB gene; relevant for Amish descent

  • Limb-Girdle Muscular Dystrophy Type 2I

    1 variant in the FKRP gene

  • MCAD Deficiency

    4 variants in the ACADM gene; relevant for European descent

  • Maple Syrup Urine Disease Type 1B

    2 variants in the BCKDHB gene; relevant for Ashkenazi Jewish descent

  • Mucolipidosis Type IV

    1 variant in the MCOLN1 gene; relevant for Ashkenazi Jewish descent

  • Neuronal Ceroid Lipofuscinosis (CLN5-Related)

    1 variant in the CLN5 gene; relevant for Finnish descent

  • Neuronal Ceroid Lipofuscinosis (PPT1-Related)

    3 variants in the PPT1 gene; relevant for Finnish descent

  • Niemann-Pick Disease Type A

    3 variants in the SMPD1 gene; relevant for Ashkenazi Jewish descent

  • Nijmegen Breakage Syndrome

    1 variant in the NBN gene

  • Nonsyndromic Hearing Loss and Deafness, DFNB1 (GJB2-Related)

    2 variants in the GJB2 gene; relevant for Ashkenazi Jewish, European descent

  • Pendred Syndrome and DFNB4 Hearing Loss (SLC26A4-Related)

    6 variants in the SLC26A4 gene

  • Phenylketonuria and Related Disorders

    23 variants in the PAH gene; relevant for Irish, Northern European descent

  • Primary Hyperoxaluria Type 2

    1 variant in the GRHPR gene

  • Rhizomelic Chondrodysplasia Punctata Type 1

    1 variant in the PEX7 gene

  • Salla Disease

    1 variant in the SLC17A5 gene; relevant for Finnish, Swedish descent

  • Sickle Cell Anemia

    1 variant in the HBB gene; relevant for African American, African descent

  • Sjögren-Larsson Syndrome

    1 variant in the ALDH3A2 gene; relevant for Swedish descent

  • Tay-Sachs Disease

    4 variants in the HEXA gene; relevant for Ashkenazi Jewish, Cajun descent

  • Tyrosinemia Type I

    4 variants in the FAH gene; relevant for French Canadian, Finnish descent

  • Usher Syndrome Type 1F

    1 variant in the PCDH15 gene; relevant for Ashkenazi Jewish descent

  • Usher Syndrome Type 3A

    1 variant in the CLRN1 gene; relevant for Ashkenazi Jewish descent

  • Zellweger Syndrome Spectrum (PEX1-Related)

    1 variant in the PEX1 gene

*The 23andMe PGS test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action.
For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/